Canopus BioPharma Incorporated
Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. It also provides antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceutricals. The company was founded in 1996 as Canopus Corporation and chan… Read more
Canopus BioPharma Incorporated (CBIA) - Total Assets
Latest total assets as of May 2023: $6.15K USD
Based on the latest financial reports, Canopus BioPharma Incorporated (CBIA) holds total assets worth $6.15K USD as of May 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Canopus BioPharma Incorporated - Total Assets Trend (2013–2022)
This chart illustrates how Canopus BioPharma Incorporated’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Canopus BioPharma Incorporated - Asset Composition Analysis
Current Asset Composition (August 2022)
Canopus BioPharma Incorporated's total assets of $6.15K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 100.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2022)
This chart illustrates how Canopus BioPharma Incorporated's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Canopus BioPharma Incorporated's current assets represent 100.0% of total assets in 2022, an increase from 0.0% in 2013.
- Cash Position: Cash and equivalents constituted 100.0% of total assets in 2022, up from 0.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 75.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Canopus BioPharma Incorporated Competitors by Total Assets
Key competitors of Canopus BioPharma Incorporated based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Genimous Technology Co Ltd
SHE:000676
|
China | CN¥5.12 Billion |
|
PUC Bhd
KLSE:0007
|
Malaysia | RM188.26 Million |
|
Hunan TV & Broadcast Intermediary Co Ltd
SHE:000917
|
China | CN¥16.44 Billion |
|
Focus Media Information Technology Co Ltd
SHE:002027
|
China | CN¥23.79 Billion |
|
NanJi ECommerce Co Ltd
SHE:002127
|
China | CN¥4.84 Billion |
|
Leo Group Co Ltd
SHE:002131
|
China | CN¥21.89 Billion |
|
Foshan Saturday Shoes Co Ltd
SHE:002291
|
China | CN¥4.97 Billion |
|
Guangdong Advertising Co Ltd
SHE:002400
|
China | CN¥11.09 Billion |
Canopus BioPharma Incorporated - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Canopus BioPharma Incorporated generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Canopus BioPharma Incorporated is currently not profitable relative to its asset base.
Canopus BioPharma Incorporated - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.03 | 0.46 | 0.00 |
| Quick Ratio | 0.03 | 0.46 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-184.96K | $ -9.34K | $ -2.17 Million |
Canopus BioPharma Incorporated - Advanced Valuation Insights
This section examines the relationship between Canopus BioPharma Incorporated's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 368.3% |
| Total Assets | $4.21K |
| Market Capitalization | $0.96 USD |
Valuation Analysis
Below Book Valuation: The market values Canopus BioPharma Incorporated's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Canopus BioPharma Incorporated's assets grew by 368.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Canopus BioPharma Incorporated (2013–2022)
The table below shows the annual total assets of Canopus BioPharma Incorporated from 2013 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-08-31 | $4.21K | +368.33% |
| 2021-08-31 | $900.00 | -99.94% |
| 2014-08-31 | $1.56 Million | -10.78% |
| 2013-08-31 | $1.75 Million | -- |